The New England Journal of Statistics in Data Science logo


  • Help
Login Register

  1. Home
  2. Issues
  3. Volume 3, Issue 3 (2025)
  4. Risks in Finding Doses for a New Drug

The New England Journal of Statistics in Data Science

Submit your article Information Become a Peer-reviewer
  • Article info
  • Full article
  • More
    Article info Full article

Risks in Finding Doses for a New Drug
Volume 3, Issue 3 (2025), pp. 212–221
Naitee Ting  

Authors

 
Placeholder
https://doi.org/10.51387/25-NEJSDS081
Pub. online: 6 January 2026      Type: Research Communication      Open accessOpen Access
Area: Biomedical Research

Published
6 January 2026

Abstract

The biggest risk in new drug development is either unaware of, or under-estimate the potential risks in designing clinical trials. Among all challenges in drug development, the most critical one is about finding the appropriate dose(s) for the study drug in treating patients. Designing dose finding clinical trials involves in many potential risks. In practice, most of the expensive failures in drug development originated not from “We did not know”, rather, the mistake is “We thought we knew”. In other words, greatest risks came from lack of awareness of underlying assumptions. This manuscript attempts to discuss some of these risks and make recommendations to reduce risks in the design of dose finding clinical trials. This is not a complete list of risks, but it is only starting the discussion.

References

[1] 
Evans, S. Fundamentals of clinical trial design. Journal of experimental stroke and translational medicine 3(1) 19–27 (2010).
[2] 
Evans, S. and Ting, N. Fundamental Concepts for New Clinical Trialists. Chapman Hall/CRC (2015).
[3] 
Fisher, R. The Design of Experiments. Hafner Press, A Division of Macmillian Publishing Co. Inc., New York, NY, 10022 (1971).
[4] 
Pinheiro, J. C., Bretz, F. and Branson, M. Analysis of Dose-Response Studies – Modeling Approaches, Chapter 10 of book Dose Finding in Drug Development. Springer (2006).
[5] 
Ting, N. Phase 2 Clinical Development in Treating Chronic Diseases. Drug Information Journal 45(4) 431–442 (2011).
[6] 
Ting, N., Chen, D., Ho, S. and Capppelleri, J. Phase II Clinical Development of New Drugs. Springer (2017).
[7] 
Ye, J., Tian, H., Guo, X. T. and Ting, N. Clinical Trial Design – What is the Critical Question for Decision-Making? Statistics in Biosciences (2023).
[8] 
Zhang, Y., Deng, Q., Wang, S. and Ting, N. A Simple and Efficient Statistical Approach for Designing an Early Phase II Clinical Trial: Ordinal Linear Contrast Test. In New Advances in Statistics and Data Science 179–196. Springer (2017). MR3586117

Full article PDF XML
Full article PDF XML

Copyright
© 2025 New England Statistical Society
by logo by logo
Open access article under the CC BY license.

Metrics
since December 2021
44

Article info
views

15

Full article
views

34

PDF
downloads

9

XML
downloads

Export citation

Copy and paste formatted citation
Placeholder

Download citation in file


Share


RSS

The New England Journal of Statistics in Data Science

  • ISSN: 2693-7166
  • Copyright © 2021 New England Statistical Society

About

  • About journal

For contributors

  • Submit
  • OA Policy
  • Become a Peer-reviewer
Powered by PubliMill  •  Privacy policy